Dianthus Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Dianthus Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 95% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 0 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-570.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 96% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 0/3Sales grew in 1 of the last 3 years; profit grew in 0 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 68%
Sales fell 68% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-68% / +539%In 3 years sales changed by -68% while total assets changed by +539%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-351.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 95% of Healthcare companies in United States.
Cash Cushion Ratio
+9%Cash, after subtracting all debt, equals 9% of its market value (net cash).
Higher than 50% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Dianthus Therapeutics, Inc. made a loss over the last year. Dianthus Therapeutics, Inc. owes $0.03 for every $1 it owns. Dianthus Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossDianthus Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.75The share price is 3.75 times Dianthus Therapeutics, Inc.'s book value per share, higher than 63% of Healthcare companies in United States.
Market cap
$4.4 BThe total market value of all of Dianthus Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 83% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.2 BWhat Dianthus Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$20.95Net worth divided by the number of shares. The share price of $78.53 is 3.7 times this, which is the P/B above.
Return on equity (ROE)
-26.1%Dianthus Therapeutics, Inc. lost 26.1% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
Owes vs Owns
0.03×Dianthus Therapeutics, Inc. owes $0.03 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Dividend yield
NoneDianthus Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-67%Revenue fell 67% in the year to Dec 2025, and shrank 32% a year on average over 3 years.
Profit growth
LossDianthus Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-7973.3%Dianthus Therapeutics, Inc. lost $7973 for every $100 of revenue.
Cash vs debt
Net cashDianthus Therapeutics, Inc. held $403 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Dianthus Therapeutics, Inc.: $4.4 B ÷ $1.2 B (30 Jun 2026) = 3.7.
What is Dianthus Therapeutics, Inc.'s return on equity?
Dianthus Therapeutics, Inc. lost 26.1% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
How much does Dianthus Therapeutics, Inc. owe compared with what it owns?
Dianthus Therapeutics, Inc. owes $0.03 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Does Dianthus Therapeutics, Inc. pay a dividend?
No. Dianthus Therapeutics, Inc. does not currently pay a dividend.
Is Dianthus Therapeutics, Inc.'s revenue growing?
Revenue fell 67% in the year to Dec 2025, and shrank 32% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.